Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira® in healthy subjects - Hyland, Elizabeth; Mant, Tim; Vlachos, Pantelis; Attkins, Neil; Ullmann, Martin; Roy, Sanjeev; Wagner, Volker (British journal of clinical pharmacology, 2016)
Keywords: adalimumab; Adalimumab - adverse effects; Adalimumab - blood; Adalimumab - immunology; Adalimumab - metabolism; Adolescent; Adult; Biological Availability; biosimilar; Biosimilar Pharmaceuticals - adverse effects; Biosimilar Pharmaceuticals - blood; Biosimilar Pharmaceuticals - pharmacokinetics; Clinical Trials; Double-Blind Method; Female; Healthy Volunteers; Humans; Male; Middle Aged; pharmacokinetics; safety; Therapeutic Equivalency; Young Adult; pharmacokinetics; safety; adalimumab; biosimilar